SEVERE HYPERTRIGLYCERIDEMIA (SHTG)
Clinical trials for SEVERE HYPERTRIGLYCERIDEMIA (SHTG) explained in plain language.
Never miss a new study
Get alerted when new SEVERE HYPERTRIGLYCERIDEMIA (SHTG) trials appear
Sign up with your email to follow new studies for SEVERE HYPERTRIGLYCERIDEMIA (SHTG), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Weekly shot aims to tame dangerous fat levels in the blood
Disease control Not yet recruitingThis Phase 3 trial tests an investigational biologic called DR10624, given as a weekly injection, in adults with severe hypertriglyceridemia (very high blood fats) who are already on standard lipid-lowering therapy. The study compares two doses of DR10624 against a placebo to see…
Matched conditions: SEVERE HYPERTRIGLYCERIDEMIA (SHTG)
Phase: PHASE3 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Gene-Editing shot aims to slash dangerous fat levels in blood
Disease control Not yet recruitingThis early study tests a new gene-editing treatment called CS-121 in 15 adults with severe high triglycerides (a type of fat in the blood) that hasn't been controlled by standard treatments. The therapy uses tiny fat particles to deliver a gene editor that targets the APOC3 gene …
Matched conditions: SEVERE HYPERTRIGLYCERIDEMIA (SHTG)
Phase: EARLY_PHASE1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC